PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
bluebird bio, Inc. (BLUE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS09609G1004
CUSIP09609G100
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$196.60M
EPS-$0.63
PEG Ratio0.32
Revenue (TTM)$21.73M
Gross Profit (TTM)-$247.24M
EBITDA (TTM)-$131.77M
Year Range$0.88 - $5.53
Target Price$4.16
Short %16.48%
Short Ratio2.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


bluebird bio, Inc.

Popular comparisons: BLUE vs. SCHD, BLUE vs. SPY, BLUE vs. IBRX, BLUE vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in bluebird bio, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%NovemberDecember2024FebruaryMarchApril
-66.91%
18.82%
BLUE (bluebird bio, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

bluebird bio, Inc. had a return of -30.90% year-to-date (YTD) and -72.20% in the last 12 months. Over the past 10 years, bluebird bio, Inc. had an annualized return of -22.80%, while the S&P 500 had an annualized return of 10.42%, indicating that bluebird bio, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-30.90%5.05%
1 month-30.39%-4.27%
6 months-66.89%18.82%
1 year-72.20%21.22%
5 years (annualized)-59.67%11.38%
10 years (annualized)-22.80%10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-26.09%36.27%-7.91%
2023-19.36%-2.96%29.49%-63.87%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BLUE is 17, indicating that it is in the bottom 17% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of BLUE is 1717
bluebird bio, Inc.(BLUE)
The Sharpe Ratio Rank of BLUE is 1919Sharpe Ratio Rank
The Sortino Ratio Rank of BLUE is 2323Sortino Ratio Rank
The Omega Ratio Rank of BLUE is 2222Omega Ratio Rank
The Calmar Ratio Rank of BLUE is 1111Calmar Ratio Rank
The Martin Ratio Rank of BLUE is 1010Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for bluebird bio, Inc. (BLUE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BLUE
Sharpe ratio
The chart of Sharpe ratio for BLUE, currently valued at -0.64, compared to the broader market-2.00-1.000.001.002.003.00-0.64
Sortino ratio
The chart of Sortino ratio for BLUE, currently valued at -0.64, compared to the broader market-4.00-2.000.002.004.00-0.64
Omega ratio
The chart of Omega ratio for BLUE, currently valued at 0.91, compared to the broader market0.501.001.500.91
Calmar ratio
The chart of Calmar ratio for BLUE, currently valued at -0.72, compared to the broader market0.001.002.003.004.005.00-0.72
Martin ratio
The chart of Martin ratio for BLUE, currently valued at -1.42, compared to the broader market0.0010.0020.0030.00-1.42
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current bluebird bio, Inc. Sharpe ratio is -0.64. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.64
1.81
BLUE (bluebird bio, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


bluebird bio, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.37%
-4.64%
BLUE (bluebird bio, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the bluebird bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the bluebird bio, Inc. was 99.40%, occurring on Feb 5, 2024. The portfolio has not yet recovered.

The current bluebird bio, Inc. drawdown is 99.37%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.4%Mar 13, 20181484Feb 5, 2024
-81.36%Jun 1, 2015241May 12, 2016399Dec 11, 2017640
-49.91%Jul 17, 201389Nov 19, 2013143Jun 17, 2014232
-25.15%Jun 23, 201417Jul 16, 201471Oct 24, 201488
-19.58%Jan 15, 201517Feb 9, 201517Mar 5, 201534

Volatility

Volatility Chart

The current bluebird bio, Inc. volatility is 26.86%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%NovemberDecember2024FebruaryMarchApril
26.86%
3.30%
BLUE (bluebird bio, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of bluebird bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items